Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825955 · ClinicalTrials.gov registry record · Phase 3
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT00825955 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 587 participants.
The verdict
NCT00825955, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
Interventions
- OTHER Placebo
- DRUG Brivanib
- PROCEDURE Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2009-02-17 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825955
The ClinicalTrials.gov registry entry for NCT00825955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00825955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00825955 about?
NCT00825955 is a clinical study titled "Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment". The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
What is the current status of trial NCT00825955?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2009-02-17. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT00825955?
The interventions under investigation include: Placebo (OTHER), Brivanib (DRUG), Best Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT00825955?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.